Navigation Links
KemPharm, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
Date:8/6/2014

CORALVILLE, Iowa, Aug. 6, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Canaccord Genuity 34th Annual Growth Conference at the InterContinental Boston Hotel in Boston, MA.

Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's clinical, regulatory and commercial strategy for KP201, the company's lead clinical candidate for the treatment of acute moderate to moderately severe pain.  Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). 

Details of KemPharm's presentation are as follows: Event:Canaccord Genuity 34th Annual Growth ConferenceDate: August 13, 2014Time: 11:00 a.m. – 11:25 a.m. ETLocation:InterContinental Boston HotelAbout KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  For more information on KemPharm, please visit the company's website at www.kempharm.com.For KemPharm, Inc:Media / Investor Contacts:Gordon K. "Rusty" Johnson

319-665-2575

info@kempharm.com

Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.375.2665 / 2664

jrando@tiberend.com

jdrumm@tiberend.com


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
2. MEI Pharma To Present At Wedbush PacGrow Life Sciences And Canaccord Genuity Growth Conferences
3. Cynosure to Present at Canaccord Genuity 34th Annual Growth Conference
4. IRIDEX to Present at 2014 Wedbush Life Sciences Management Access Conference
5. HeartWare Presentation At The Canaccord Genuity 34th Annual Growth Conference To Be Webcast
6. CryoLife to Present at 34th Annual Canaccord Genuity Growth Conference
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference
9. Cardica To Present At 2014 Wedbush PacGrow Life Sciences Management Access Conference
10. Thoratec Presentation At Canaccord Genuity Growth Conference To Be Webcast
11. Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):